Stanley Druckenmiller Ultragenyx Pharmaceutical Inc. Transaction History
Duquesne Family Office LLC
- $2.95 Billion
- Q3 2024
A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Duquesne Family Office LLC holds 85,445 shares of RARE stock, worth $3.78 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
85,445Holding current value
$3.78 Million% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.6MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$440 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$248 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$226 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$184 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$136 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.1B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...